{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:12:38Z","timestamp":1780085558048,"version":"3.54.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002798.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000}}],"reference-count":111,"publisher":"Wiley","license":[{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002798.pub3","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T16:35:40Z","timestamp":1501086940000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy"],"prefix":"10.1002","author":[{"given":"Ee Teng","family":"Goh","sequence":"first","affiliation":[{"name":"Division of Medicine, Royal Free Campus, University College London; UCL Institute for Liver & Digestive Health; Rowland Hill Street Hampstead London UK NW3 2PF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette L","family":"Andersen","sequence":"additional","affiliation":[{"name":"Rigshospitalet; Department of Hepatology; Blegdamsvej 9 Dept. 2121 Copenhagen Denmark 2100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha Y","family":"Morgan","sequence":"additional","affiliation":[{"name":"Division of Medicine, Royal Free Campus, University College London; UCL Institute for Liver & Digestive Health; Rowland Hill Street Hampstead London UK NW3 2PF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital Hvidovre; Gastrounit, Medical Division; Kettegaards Alle Hvidovre Denmark 2650"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,26]]},"reference":[{"key":"10.1002\/14651858.CD002798.pub3-BIB0001|cit1","first-page":"179","article-title":"Effects of flumazenil on subclinical hepatic encephalopathy (SHE): preliminary data","volume":"23","author":"Amodio","year":"1993","journal-title":"Italian Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002798.pub3-BIB0002|cit2","first-page":"88","article-title":"Effects of flumazenil on subclinical hepatic encephalopathy","volume":"18","author":"Amodio","year":"1993","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2281.1997.05656.x","article-title":"The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: a double-blind placebo-controlled study","volume":"17","author":"Amodio","year":"1997","journal-title":"Clinical Physiology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/hep.510280212","article-title":"Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, crossover study","volume":"28","author":"Barbaro","year":"1998","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00063110-199806000-00004","article-title":"Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study","volume":"5","author":"Barbaro","year":"1998","journal-title":"European Journal of Emergency Medicine"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0006|cit6","first-page":"325","article-title":"Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomised, placebo study","volume":"7","author":"Cadranel","year":"1995","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002798.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0168-8278(91)91390-3","article-title":"Immediate improvement of hepatic encephalopathy (HE) in cirrhotic patients by flumazenil. Results of a double-blind crossover study","volume":"13","author":"Cadranel","year":"1991","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0008|cit8","first-page":"A216","article-title":"The immediate effect on the clinical grade and electroencephalogram of cirrhotic patients with hepatic encephalopathy","volume":"15","author":"Younsi","year":"1991","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0009|cit9","first-page":"118","article-title":"The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients. A prospective, randomised, double-blind, placebo-controlled study","volume":"133","author":"Dursun","year":"2003","journal-title":"Swiss Medical Weekly"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3940(99)00817-4","article-title":"The effect of flumazenil on visual event-related potentials of clinically non-encephalopathic patients with cirrhosis","volume":"276","author":"Giger-Mateeva","year":"1999","journal-title":"Neuroscience Letters"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1011662411913","article-title":"Visual event-related potentials in cirrhotic patients without overt encephalopathy: the effects of flumazenil","volume":"16","author":"Jones","year":"2001","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02246294","article-title":"Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy","volume":"119","author":"Gooday","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0013-4694(95)00200-6","article-title":"Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double-blind, randomised, placebo-controlled multicentre trial","volume":"98","author":"Groeneweg","year":"1996","journal-title":"Electroencephalography and Clinical Neurophysiology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/gut.39.2.319","article-title":"Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study","volume":"39","author":"Gyr","year":"1996","journal-title":"Gut"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0016-5085(08)81871-9","article-title":"Short-term effects of flumazenil in early stage of portosystemic encephalopathy (PSE): a placebo-controlled, prospective, randomized study","volume":"120","author":"Lotterer","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0016|cit16","first-page":"A942","article-title":"Treatment of portosystemic encephalopathy with the benzodiazepine-receptor antagonist flumazenil (a randomised, double-blind, placebo-controlled, multicenter study","volume":"106","author":"Meier","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0017|cit17","first-page":"R172","article-title":"The clinical and electroencephalographic effects of flumazenil in acute hepatic encephalopathy","volume":"10","author":"Hermant","year":"1991","journal-title":"Annales Francaises d'Anaesthesie et de Reanimation"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(89)91165-3","article-title":"Flumazenil and hepatic encephalopathy","volume":"1","author":"Klotz","year":"1989","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1590-8658(00)80027-4","article-title":"Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomised placebo controlled study","volume":"32","author":"Lacetti","year":"2000","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0020|cit20","first-page":"79","article-title":"Clinical study of flumazenil on severe hepatic encephalopathy","volume":"12","author":"Li","year":"2009","journal-title":"Practical Pharmacy and Clinical Remedies"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0021|cit21","first-page":"32","article-title":"Flumazenil in cirrhotic patients in hepatic coma: a randomised double-blind placebo-controlled crossover trial","volume":"19","author":"Pomier-Layrargues","year":"1994","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0022|cit22","first-page":"572","article-title":"Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study","volume":"19","author":"Rijt","year":"1995","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0024|cit23","volume-title":"Hepatic Encephalopathy: Clinical and Experimental Studies","author":"Rijt","year":"1991"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0023|cit24","first-page":"4","article-title":"Flumazenil therapy for hepatic encephalopathy: a double-blind cross-over study","volume":"10","author":"Rijt","year":"1989","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0025|cit25","first-page":"355","article-title":"Flumazenil in the treatment of cirrhotic patients with hepatic encephalopathy: a randomised doubled-blind clinical trial","volume":"18","author":"Zhu","year":"1998","journal-title":"Chinese Journal of Digestion"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/0016-5085(89)90647-1","article-title":"Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans","volume":"97","author":"Bansky","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF01701483","article-title":"Flumazenil in the treatment of hepatic encephalopathy in children with fulminant liver failure","volume":"21","author":"Devictor","year":"1995","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0028|cit28","first-page":"32","article-title":"Effects of flumazenil (benzodiazepine antagonist) in hepatic coma","volume":"18","author":"Golubovic","year":"1999","journal-title":"Archives of Gastroenterohepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(88)90587-9","article-title":"Improvement of hepatic encephalopathy treated with flumazenil","volume":"2","author":"Grimm","year":"1988","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0030|cit30","first-page":"56","article-title":"A prospective, controlled study on flumazenil therapy for portal-systemic shunt encephalopathy","volume":"7","author":"Jia","year":"1999","journal-title":"Chinese Journal of Hepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF02246197","article-title":"Differential effects of flumazenil in alcoholic and nonalcoholic cirrhotic patients","volume":"120","author":"Kapczinski","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0750-7658(05)80259-X","article-title":"Treatment of hepatic encephalopathy with flumazenil","volume":"9","author":"Marsepoil","year":"1990","journal-title":"Annales Francaises d'Anesthesie et de Reanimation"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0033|cit33","first-page":"210","article-title":"Evoked potentials and the effect of flumazenil in patients with liver cirrhosis","volume":"74","author":"Ozyilkan","year":"1997","journal-title":"East African Medical Journal"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0034|cit34","first-page":"103","article-title":"Flumazenil and lactulose combination therapy for hepatic encephalopathy","volume":"10","author":"Wu","year":"2001","journal-title":"Chinese Journal of Modern Medicine"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0035|cit35","unstructured":"Treatment of Hepatic Encephalopathy with Flumazenil and Change in Cortical Gamma Aminobutyric Acid Levels in MRS [magnetic resonance spectroscopy]. Ongoing study"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.neuint.2007.05.004","article-title":"The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy","volume":"52","author":"Ahboucha","year":"2008","journal-title":"Neurochemistry International"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1399-6576.1990.tb03174.x","article-title":"Pharmacology of Dormicum (midazolam) and Anexate (flumazenil)","volume":"92","author":"Amrein","year":"1990","journal-title":"Acta Anaesthesiologica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1053\/j.gastro.2008.07.021","article-title":"Inhibitory control test for the diagnosis of minimal hepatic encephalopathy","volume":"135","author":"Bajaj","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/hep.23216","article-title":"Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy","volume":"50","author":"Bajaj","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1053\/j.gastro.2010.02.015","article-title":"Persistence of cognitive impairment after resolution of overt hepatic encephalopathy","volume":"138","author":"Bajaj","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2011.04590.x","article-title":"Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement","volume":"33","author":"Bajaj","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/hep.1840070403","article-title":"Mechanism of the selective response of cirrhotics to benzodiazepines. Model experiments with triazolam","volume":"7","author":"Batki","year":"1987","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003495-199142060-00010","article-title":"Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist","volume":"42","author":"Brogden","year":"1991","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis","volume":"30","author":"Bustamante","year":"1999","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jsbmb.2015.11.006","article-title":"Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities.","volume":"160","author":"Butterworth","year":"2016","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1111\/j.1440-1746.1997.tb00512.x","article-title":"Evoked potentials in liver diseases","volume":"12","author":"Chu","year":"1997","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial","volume":"72","author":"Conn","year":"1977","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1023\/A:1021926405944","article-title":"1H magnetic resonance in the study of hepatic encephalopathy in humans","volume":"17","author":"C\u00f3rdoba","year":"2002","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","article-title":"Survival and prognostic indicators in compensated and decompensated cirrhosis","volume":"31","author":"D'Amico","year":"1986","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(92)91188-A","article-title":"Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver","volume":"103","author":"Jongh","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.05.042","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases","volume":"61","author":"American Association for the Study of Liver Diseases","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0056|cit56","first-page":"1334","article-title":"Systemic complications of liver disease","volume-title":"Sleisenger and Fortran's Gastrointestinal and Liver Disease. Pathology, Diagnosis, Management","author":"Fitz","year":"1998"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0057|cit57","unstructured":"Gluud C Nikolova D Klingenberg SL Cochrane Hepato-Biliary Group About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 6. Art. No.: LIVER"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2036.2002.01191.x","article-title":"Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis","volume":"16","author":"Goulenok","year":"2002","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0059|cit59","unstructured":"Brozek J Oxman A Sch\u00fcnemann H GRADEpro 2008"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0060|cit60","first-page":"14","article-title":"Acute liver failure","volume":"7014","author":"Grippon","year":"1988","journal-title":"Encyclopedia Medicine Chirurgie"},{"issue":"1","key":"10.1002\/14651858.CD002798.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0013-4694(95)00200-6","article-title":"Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial","volume":"98","author":"Groeneweg","year":"1996","journal-title":"Electroencephalography and Clinical Neurophysiology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/hep.510280108","article-title":"Subclinical hepatic encephalopathy impairs daily functioning","volume":"28","author":"Groeneweg","year":"1998","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1478-3231.2009.02030.x","article-title":"Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines","volume":"29","author":"Gu\u00e9rit","year":"2009","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0168-8278(00)80110-5","article-title":"Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?","volume":"32","author":"Haussinger","year":"2000","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1740774508091600","article-title":"Imputation methods for missing outcome data in meta-analysis of clinical trials","volume":"5","author":"Higgins","year":"2008","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bcp.12023","article-title":"Benzodiazepine dependence and its treatment with low dose flumazenil","volume":"77","author":"Hood","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200105243442106","article-title":"Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment","volume":"344","author":"Hrobjartsson","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0069|cit69","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0070|cit70","article-title":"Hepatic encephalopathy","volume-title":"The Liver: Biology and Pathobiology","author":"Jones","year":"1988"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0071|cit71","first-page":"549","article-title":"Effect of extracorporeal liver perfusion on the electroencephalogram of patients in coma due to acute liver failure","volume":"42","author":"Kennedy","year":"1973","journal-title":"Quarterly Journal of Medicine"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/jhep.2002.30957","article-title":"Critical flicker frequency for quantification of low-grade hepatic encephalopathy","volume":"35","author":"Kircheis","year":"2002","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2009.08.003","article-title":"Hepatic encephalopathy and fitness to drive","volume":"137","author":"Kircheis","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11011-011-9242-1","article-title":"Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease","volume":"26","author":"Lauridsen","year":"2011","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00004691-198401040-00001","article-title":"Electroencephalography in diffuse encephalopathies","volume":"1","author":"Markand","year":"1984","journal-title":"Journal of Clinical Neurophysiology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/B:MEBR.0000043977.11113.2a","article-title":"Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach","volume":"19","author":"Montagnese","year":"2004","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1592\/phco.30.pt2.28S","article-title":"Pharmacoeconomics of hepatic encephalopathy","volume":"30","author":"Neff","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0078|cit78","first-page":"875","article-title":"Fulminant hepatitis: an experience based on 137 cases. II. Course and prognosis","volume":"1","author":"Nusinovici","year":"1977","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/0140-6736(91)92920-W","article-title":"Regional cerebral blood flow and cognitive function in patients with chronic liver disease","volume":"337","author":"O'Carroll","year":"1991","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-2008-1040782","article-title":"Methods of assessing hepatic encephalopathy","volume":"3","author":"Pappas","year":"1983","journal-title":"Seminars in Liver Disease"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(57)90005-3","article-title":"The electroencephalograph in liver disease","volume":"273","author":"Parsons-Smith","year":"1957","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encephalopathy","volume":"25","author":"Poordad","year":"2007","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1478-3231.2009.02009.x","article-title":"Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines","volume":"29","author":"Randolph","year":"2009","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0084|cit84","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/ajg.2010.413","article-title":"Minimal hepatic encephalopathy is associated with falls","volume":"106","author":"Roman","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/0962280214521349","article-title":"Analysis of cross-over studies with missing data","volume":"24","author":"Rosenkranz","year":"2015","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/scitranslmed.3004685","article-title":"Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors","volume":"4","author":"Rye","year":"2012","journal-title":"Science Translational Medicine"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bmj.282.6260.263","article-title":"A 20-year prospective study of cirrhosis","volume":"282","author":"Saunders","year":"1981","journal-title":"British Medical Journal (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovic","year":"2012","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovic","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/BF01367675","article-title":"Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive","volume":"26","author":"Schomerus","year":"1981","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1023\/A:1020645110880","article-title":"Neuropsychological aspects of portal-systemic encephalopathy","volume":"13","author":"Schomerus","year":"1998","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/lt.21593","article-title":"Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation","volume":"15","author":"Sotil","year":"2009","journal-title":"Liver Transplantation"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0095|cit95","volume-title":"EEG Primer","author":"Spehlman","year":"1991"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0096|cit96","unstructured":"Stata Corp Stata 14 2007"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.cgh.2012.05.016","article-title":"In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/lt.21129","article-title":"Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease","volume":"13","author":"Stewart","year":"2007","journal-title":"Liver Transplantation"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF02098881","article-title":"Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy","volume":"9","author":"Taylor-Robinson","year":"1994","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(74)91639-0","article-title":"Assessment of coma and impaired consciousness. A practical scale","volume":"13","author":"Teasdale","year":"1974","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0101|cit101","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for Trial Sequential Analysis (TSA), 2011 ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0102|cit102","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis 2011"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"9269","DOI":"10.1073\/pnas.83.23.9269","article-title":"Modulation of y-aminobutyric acid-mediated inhibitory synaptic currents in dissociated cortical cell cultures","volume":"83","author":"Vicini","year":"1987","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000051415","article-title":"Diagnosis of encephalopathy","volume":"59","author":"Weissenborn","year":"1998","journal-title":"Digestion"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1011654210096","article-title":"Attention deficits in minimal hepatic encephalopathy","volume":"16","author":"Weissenborn","year":"2001","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD002798.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1399-6576.1995.tb04374.x","article-title":"Pharmacology of flumazenil","volume":"108","author":"Whitwam","year":"1995","journal-title":"Acta Anaesthesiologica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD002798.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1478-3231.2012.02830.x","article-title":"Prognostic indicators of survival in patients with compensated and decompensated cirrhosis","volume":"32","author":"Zipprich","year":"2012","journal-title":"Liver International"},{"issue":"4","key":"10.1002\/14651858.CD002798.pub3-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002798.pub2","article-title":"Benzodiazepine receptor antagonists for hepatic encephalopathy","author":"Als-Nielsen","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD002798.pub3-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002798.pub2","article-title":"Benzodiazepine receptor antagonists for hepatic encephalopathy","author":"Als-Nielsen","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd002798.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002798.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:12:36Z","timestamp":1628543556000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002798.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,26]]},"references-count":111,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002798.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD002798.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,26]]}}}